Stephens Lowers OraSure Technologies (NASDAQ:OSUR) Price Target to $3.00

OraSure Technologies (NASDAQ:OSUR) had its target price cut by investment analysts at Stephens from $3.50 to $3.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the medical instruments supplier’s stock. Stephens’ target price would suggest a potential upside of 21.95% from the company’s previous close.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of OraSure Technologies in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, OraSure Technologies has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Trading Up 5.6%

Shares of OSUR stock opened at $2.46 on Wednesday. The company has a market capitalization of $176.47 million, a price-to-earnings ratio of -3.67 and a beta of 0.54. The firm has a 50-day moving average price of $3.03 and a 200 day moving average price of $2.98. OraSure Technologies has a twelve month low of $2.30 and a twelve month high of $4.31.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 5th. The medical instruments supplier reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $27.09 million during the quarter, compared to the consensus estimate of $28.96 million. OraSure Technologies had a negative net margin of 36.84% and a negative return on equity of 10.81%. OraSure Technologies has set its Q4 2025 guidance at EPS. As a group, research analysts predict that OraSure Technologies will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC acquired a new stake in shares of OraSure Technologies in the second quarter worth $26,000. Prudential Financial Inc. purchased a new position in OraSure Technologies in the second quarter valued at about $31,000. Nierenberg Investment Management Company Inc. acquired a new position in shares of OraSure Technologies during the second quarter worth about $35,000. L2 Asset Management LLC acquired a new position in shares of OraSure Technologies during the second quarter worth about $39,000. Finally, Coldstream Capital Management Inc. boosted its position in shares of OraSure Technologies by 128.2% in the second quarter. Coldstream Capital Management Inc. now owns 13,308 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 7,477 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.